undamentalytics Newsletter
Sign in

Transmedics Group, Inc. cash flow statement

In fiscal 2025, Transmedics Group, Inc.'s operations generated $193m of cash; it spent $59.3m on capital projects, leaving free cash flow of $134m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−26−32−30−29−46−1349193146
Depreciation and amortisation112238202736
Stock-based pay01271020333737
Capital spending0004121521305967
Free cash flow−26−32−31−32−58−165−8113479
Free cash flow after stock pay−27−33−33−39−68−185−1149742

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: GKOS vs TMDXNVCR vs TMDXBVS vs TMDXATRC vs TMDX

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Transmedics Group, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Transmedics Group, Inc.